Pr ecis: These findings offer a preclinical proof of concept for miR-124-based therapies to treat advanced prostate cancer.
Pr ecis: These findings suggest how a rare but highly invasive and mainly untreatable sensory cell cancer in the skin might be managed by targeted therapeutic drugs currently available in clinic. Pr ecis: These findings provide the evidence that the unfolded protein response supports the survival of disseminated tumor cells, which are under acute microenvironmental stress, with implications for defining a general predictive biomarker of metastatic relapse in cancer patients after their initial treatment.
PIK3CA H1047R Accelerates and Enhances

KRAS G12D -Driven Lung Tumorigenesis
Shon Green, Christy L. Trejo, and Martin McMahon
Pr ecis: Activating mutations in the PI3K lipid signaling pathway can act as secondary hits needed to potentiate the oncogenicity of mutant KRAS in the lung, providing mechanistic insights into the sequential steps governing tumor progression. 
ABOUT THE COVER
In CD133-positive tumor-propagating cells from glioblastoma, an intact actin cytoskeleton is required for elevated PLK1 activity, which in turn controls mitotic entry and cell polarity. Taken together, the data suggest a Plk1-driven polarity checkpoint, distinguishing CD133-positive tumor-propagating cells from autologous CD133-negative cells. Elevated PLK1 activity protects CD133-positive tumor-propagating cells from BRAF/MAPK inhibition and sensitizes them to Plk1 inhibition. Using immunocytochemistry, it was found that CD133 failed to localize to the membrane and in a polarized fashion in cells treated with actin polymerization inhibitor Latrunculin A. For details, see article by Lerner and colleagues on page 5355. To request permission to re-use all or part of this article, contact the AACR Publications Department at
